公司展示了壁报 #1201-B "Characterization of a Novel Bifunctional Anti-PD-L1 Antibody-Drug Conjugate for the Treatment of Solid Tumors" 和 478# ”A Novel Antagonist Monoclonal Antibody against Human Adenosine Receptor 2a (A2aR) for Cancer Immunotherapies”。这两个项目是安普生物在GPCR抗体，肿瘤免疫双抗和双功能ADC管线的代表性产品，已分别进入中试生产和临床前开发阶段。